- F/Y 25 Revenue improvement of 20% to 24% on the prior year - F/Y 25 Profit $12.0 million to $14.0 million an improvement of 69% to 97%. Great to see management have enough confidence of the future and increase guidance for the upcoming full year. The results were starting to roll in towards year end 2024 great to see continued momentum. After hearing the first Investor series webinar yesterday with key customer Medidata, that key partnerships positive financial results hasn't hit the books yet giving more momentum for the business. Diversifying income streams and medical studies gives more stability and earnings power to the business moving forward.
CGS Price at posting:
$1.58 Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)